

Ibandronate Sodium Cas No. : 138926-19-9

Ibandronate is used to prevent and treat certain types of bone loss (osteoporosis). Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause, as you age, Take this medication by mouth usually once a day, or as directed by your doctor.

Active Pharmaceuticals Ingredients Manufacturers



Taj Pharma PDF


Taj Pharmaceuticals Ltd.

Ibandronate Sodium

CAS No. : 138926-19-9



Molecular Formula C₉H₂₂O₇NP₂Na
Molecular Weight 341.21
CAS Number 138926-19-9

**Chemical Name**

1 Hydroxy 3(N) Methly 3(N) n
Pentylamino,1,1 Bisphosphonic Acid
Molecular Formula C₉H₂₂O₇NP₂NaH₂O
Molecular Weight 359.17

USES

Ibandronate is used to prevent and treat certain types of bone loss (osteoporosis). Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause, as you age, Take this medication by mouth usually once a day, or as directed by your doctor. Take this medication after getting up for the day, before taking your first food, beverage or other medication. Do not take it at bedtime or while you are still in bed.

PRECAUTIONS

Before taking ibandronate, tell your doctor or pharmacist if you are allergic to it; or to other bisphosphonates (e.g., alendronate, etidronate, pamidronate, risedronate); or if you have any other allergies.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have the following conditions: low blood calcium levels (hypocalcemia), inability to sit upright or stand for 60 minutes, severe kidney disease.

MISSED DOSE

If you miss a dose, do not take it later in the day. Take the medication the next morning after you remember. Do not take two tablets on the same day to catch up. Consult your doctor or pharmacist if you have any questions.

STORAGE

Store at room temperature at 77 degrees F (25 degrees C) away from light and moisture. Brief storage between 59-86 degrees F (15-30 degrees C) is permitted. Do not store in the bathroom. Keep all medicines away from children

DOSAGE

Adults

PO 2.5 mg once daily or one 150 mg tablet once monthly on the same date of each month. Take at least 60 min before the first food or drink (other than water) of the day or before taking any oral medication or supplement, including antacids, calcium, or vitamins.

Adults



Taj Pharmaceuticals Ltd.
Ibandronate Sodium

CAS NO- 138926-19-9

IV 3 mg every 3 mo administered over 15 to 30 sec.

General Advice

*** Tablets**

* Two tablet strengths are available (2.5 mg tablet for once-daily administration and 150 mg tablet for once-monthly administration). Carefully check tablet to ensure proper dose is being administered.

* Do not administer tablets with any liquid other than plain water. Administration of ibandronate tablets with food, medication, juices, mineral water, coffee, or any other beverage will reduce ibandronate absorption and efficacy.

*** Injection**

* Injection must be administered IV by a health care provider.

* Administer injection using the enclosed needle.

* Prefilled syringes are for single use only; discard unused portion.

* Do not mix injection with calcium-containing solutions or other IV administered drugs.

* If a dose is missed, administer injection as soon as it can be rescheduled. Schedule subsequent injections every 3 mo from the date of last injection and not more frequently than once every 3 mo.

* Patient must receive supplemental calcium and vitamin D.

SIDE EFFECTS

Adverse events associated with the use may include (but are not limited to) the following:

- * Dyspepsia
- * Diarrhea
- * Tooth Disorder
- * Vomiting
- * Gastritis
- * Allergic Reaction
- * Infection

- Constipation
- Influenza-like Illness
- Pain in the extremities

PRECAUTIONS

* Ibandronate, like all bisphosphonate medications, can irritate or damage the esophagus and stomach. This can lead to indigestion, heartburn, or even ulcers. Let your healthcare provider know if you notice any of these problems while taking the drug.

* It is important to get enough calcium and vitamin D (either through your diet or by supplementation). Calcium and vitamin D are necessary for rebuilding bone and preventing further bone loss.

* Ibandronate may not be recommended for people with severe kidney disease.

* In rare cases, bisphosphonates (including ibandronate) have caused a condition called osteonecrosis of the jaw. This is a serious, possibly disfiguring, problem in which the bone of the jaw dies. Often, there are symptoms (such as pain, infection, or loosening of the teeth), but sometimes there are no symptoms until a person notices exposed bone.





This problem is most common when bisphosphonates are given by IV (but is still possible when these medications are taken orally). It seems that people who have dental procedures (such as a tooth extraction) are also at higher risk. Be sure to take good care of your mouth and teeth by seeing your dentist frequently. Let your healthcare provider know right away if you think you may have osteonecrosis of the jaw.

* In rare cases, bisphosphonates (including ibandronate) can cause extreme muscle or bone pain. This usually goes away once the medication is stopped.

DRUG DESCRIPTION

Ibandronate Sodium is used in the treatment of metastatic bone disease and elevated serum calcium levels in tumours, Cancer cells, after breaking off from a primary tumour enter the main bloodstream, thereby reaching nearly all tissues of the body. Bones are one of the most common sites for these circulating cells to settle in and start growing. Metastases can occur in bones anywhere in the body, but they are mostly found in bones near the centre of the body.

(ibandronate sodium) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. In osteoporosis, where osteoclasts break down bone too quickly, inhibition of this pathway has been shown to slow bone turnover, leading to not only an attenuation of turnover but also a mean increase in bone mass. is specifically indicated for the treatment and prevention of osteoporosis in postmenopausal women



Note /Government Notification: These chemicals are designated as those that are used in the manufacture of the controlled substances and are important to the manufacture of the substances. For any (Control Substance) products Import and Export *** subjected to your country government laws /control substance ACT.

Information: The information on this web page is provided to help you to work safely, but it is intended to be an overview of hazards, not a replacement for a full Material Safety Data Sheet (MSDS). MSDS forms can be downloaded from the web sites of many chemical suppliers. Also that the information on the PTCL Safety web site, where this page was hosted, has been copied onto many other sites, often without permission. If you have any doubts about the veracity of the information that you are viewing, or have any queries, please check the URL that your web browser displays for this page. If the URL begins "www.tajapi.com/www/Denatonium Benzoate.htm/" the page is maintained by the Safety Officer in Physical Chemistry at Oxford University. If not, this page is a copy made by some other person and we have no responsibility for it.

The Controlled Substances Act (CSA) was enacted into law by the Congress of the United States as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970.[1] The CSA is the federal U.S. drug policy under which the manufacture, importation, possession, use and distribution of certain substances is regulated. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs

This document plus the full buyer/ prescribing information, prepared for health professionals can be found at:

<http://www.tajapi.com>

or by contacting the sponsor, Taj Pharmaceuticals Limited., at:
91 022 30601000.

This leaflet was prepared by
Taj Pharmaceuticals Limited,
Mumbai (India).

MPSTJ278

Last revised: 29 August 2009